Cargando…

Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy

BACKGROUND: Multi-step testing might enhance performance of the prostate cancer diagnostic pipeline. Using PSA >1 ng/ml for first-line risk stratification and the Stockholm 3 Model (S3M) blood-test >10% risk of Gleason Score > 7 prostate cancer to inform biopsy decisions has been suggested....

Descripción completa

Detalles Bibliográficos
Autores principales:	Nordström, Tobias, Adolfsson, Jan, Grönberg, Henrik, Eklund, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627473/ https://www.ncbi.nlm.nih.gov/pubmed/28974201 http://dx.doi.org/10.1186/s12894-017-0281-8

Ejemplares similares

The impact of different prostate-specific antigen (PSA) testing intervals on Gleason score at diagnosis and the risk of experiencing false-positive biopsy recommendations: a population-based cohort study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study
por: Palsdottir, Thorgerdur, et al.
Publicado: (2019)

Does a novel diagnostic pathway including blood-based risk prediction and MRI-targeted biopsies outperform prostate cancer screening using prostate-specific antigen and systematic prostate biopsies? - protocol of the randomised study STHLM3MRI
por: Nordström, Tobias, et al.
Publicado: (2019)

Prognostic value of perineural invasion in prostate needle biopsies: a population-based study of patients treated by radical prostatectomy
por: Ström, Peter, et al.
Publicado: (2020)

Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening
por: Andersson, Joel, et al.
Publicado: (2022)

Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
por: Beckmann, Kerri, et al.
Publicado: (2019)

External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort
por: Chandra Engel, Jan, et al.
Publicado: (2022)

Validating fPSA Glycoprofile as a Prostate Cancer Biomarker to Avoid Unnecessary Biopsies and Re-Biopsies
por: Bertok, Tomas, et al.
Publicado: (2020)

Does normalizing PSA after successful treatment of chronic prostatitis with high PSA value exclude prostatic biopsy?
por: Azab, Sherif, et al.
Publicado: (2012)

Prostate biopsy for elevated prostate specific antigen (PSA) – Indian perspective
por: Ragavan, N.
Publicado: (2014)

The Relationship between Prostate Biopsy Results and PSA and Free PSA Ratio Changes in Elevated Serum PSA Patients with and without Antibiotherapy
por: Duran, Mesut Berkan, et al.
Publicado: (2020)

A Comparative Performance Analysis of Total PSA, Percentage Free PSA, PSA Velocity, and PSA Density versus the Detection of Primary Circulating Prostate Cells in Predicting Initial Prostate Biopsy Findings in Chilean Men
por: Murray, Nigel P., et al.
Publicado: (2014)

Predictors of adverse pathology on radical prostatectomy specimen in men initially enrolled in active surveillance for low-risk prostate cancer
por: Björnebo, Lars, et al.
Publicado: (2020)

The STHLM3-model, Risk-based Prostate Cancer Testing Identifies Men at High Risk Without Inducing Negative Psychosocial Effects
por: Koitsalu, Marie, et al.
Publicado: (2021)

The economic burden of prostate cancer – a Swedish prevalence-based register study
por: Hao, Shuang, et al.
Publicado: (2020)

A Head-to-head Comparison of Prostate Cancer Diagnostic Strategies Using the Stockholm3 Test, Magnetic Resonance Imaging, and Swedish National Guidelines: Results from a Prospective Population-based Screening Study
por: Waldén, Mauritz, et al.
Publicado: (2022)

Is prostate specific antigen (PSA) density necessary in selecting prostate cancer patients for active surveillance and what should be the cutoff in the Asian population?
por: Tsang, Chiu-Fung, et al.
Publicado: (2019)

Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result
por: Fiamegos, Alexandros, et al.
Publicado: (2016)

Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0–10.0 ng/ml
por: Chen, Rui, et al.
Publicado: (2015)

Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing
por: Pashayan, N, et al.
Publicado: (2006)

Predictors of participation in risk-based prostate cancer screening
por: Koitsalu, Marie, et al.
Publicado: (2018)

Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance
por: Kotb, A F, et al.
Publicado: (2011)

Identifying Prostate Cancer Among Men with Lower Urinary Tract Symptoms
por: Nordström, Tobias, et al.
Publicado: (2021)

Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
por: Beckmann, Kerri, et al.
Publicado: (2019)

Age-Specific Prostate Specific Antigen Cutoffs for Guiding Biopsy Decision in Chinese Population
por: Na, Rong, et al.
Publicado: (2013)

Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA
por: Müller, Stig, et al.
Publicado: (2018)

Prostate-specific antigen kinetics contributes to decision making for biopsy referral: the predictive implication for PSA retest in patients with elevated PSA levels
por: Kobayashi, Minoru, et al.
Publicado: (2023)

PSA change after antibiotic treatment should not affect decision-making on performing a prostate biopsy
por: KAYALI, Yunus, et al.
Publicado: (2022)

Incorporating Magnetic Resonance Imaging and Biomarkers in Active Surveillance Protocols - Results From the Prospective Stockholm3 Active Surveillance Trial (STHLM3AS)
por: Olsson, Henrik, et al.
Publicado: (2020)

Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)
por: Stephan, Carsten, et al.
Publicado: (2014)

Incorporating Known Genetic Variants Does Not Improve the Accuracy of PSA Testing to Identify High Risk Prostate Cancer on Biopsy
por: Gilbert, Rebecca, et al.
Publicado: (2015)

Urinary PSA and Serum PSA for Aggressive Prostate Cancer Detection
por: Höti, Naseruddin, et al.
Publicado: (2023)

Assessment of PSA-Age volume score in predicting positive prostate biopsy findings in Turkey
por: Uçer, Oktay, et al.
Publicado: (2015)

Does prostate-specific antigen (PSA) mass or free PSA mass improve the accuracy of predicting total prostate volume in relation to obesity in men with biopsy-proven benign prostatic hyperplasia?
por: Jung, Jin-Woo, et al.
Publicado: (2019)

Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4–10 ng ml(−1)
por: Tan, Lincoln GL, et al.
Publicado: (2017)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
por: De Laere, Bram, et al.
Publicado: (2021)

Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy
por: Agnihotri, Shalini, et al.
Publicado: (2014)

Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies
por: Lantz, Anna, et al.
Publicado: (2020)

PSA Based Biomarkers, Imagistic Techniques and Combined Tests for a Better Diagnostic of Localized Prostate Cancer
por: Munteanu, Vlad Cristian, et al.
Publicado: (2020)

Prostate Cancer Detection and Prognosis: From Prostate Specific Antigen (PSA) to Exosomal Biomarkers
por: Filella, Xavier, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_urlnv00pfefnro7sboetqktckt